Skip to main content

Market Overview

Jefferies: 10 Buyout Targets To Own During The M&A Boom

Share:
Jefferies: 10 Buyout Targets To Own During The M&A Boom

In a new report, analysts at Jefferies discussed the current merger and acquisition environment. The report included a breakdown of recent deals and a list of potential buyout targets that investors should consider.

Changing M&A Philosophy

M&A activity has been steadily rising in recent years, and analysts note that it is now approaching pre-crisis highs.

However, analysts point out that the spirit of recent M&A activity is different than it was during past M&A booms. Instead of acquiring trophy assets, growth targets or sources of new revenue streams, analysts see many more companies acquiring targets with the intention of lowering operational costs.

“This is a significant change in M&A philosophy and is a recognition that global growth is unlikely to be so strong that companies need to increase capacity through greenfield expansion,” analysts explain.

Latest Deals

Just last week, FedEx Corporation (NYSE: FDX) announced that it was buying TNT Express in an all-cash deal that will combine the third and fourth-largest European delivery services.

This latest deal comes on the heels of several other recent blockbusters. Royal Dutch Shell Plc (NYSE: RDS-A)(NYSE: RDS-B) made a 45 billion pound sterling offer to buy BG Group and potentially form the world’s largest LNG producer. Holcim and Lafarge have a 41 billion-euro deal on the table to potentially form the world’s largest cement company. Finally, Warren Buffett played a critical role in the recent headline-grabbing Heinz/Kraft Foods Group Inc (NASDAQ: KRFT) deal.

Buyout Targets

Jefferies recommends buying the following 10 potential M&A targets:

1. Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)
2. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX)
3. Seattle Genetics, Inc. (NASDAQ: SGEN)
4. Sangamo Biosciences, Inc. (NASDAQ: SGMO)
5. DHT Holdings Inc (NYSE: DHT)
6. BioScrip Inc (NASDAQ: BIOS)
7. OraSure Technologies, Inc. (NASDAQ: OSUR)
8. Sonus Networks, Inc. (NASDAQ: SONS)
9. NuVasive, Inc. (NASDAQ: NUVA)
10. Allscripts Healthcare Solutions Inc (NASDAQ: MDRX)

Latest Ratings for FDX

DateFirmActionFromTo
Jun 2021Raymond JamesMaintainsOutperform
Jun 2021Morgan StanleyMaintainsEqual-Weight
May 2021KeybancMaintainsOverweight

View More Analyst Ratings for FDX
View the Latest Analyst Ratings

 

Related Articles (FDX)

View Comments and Join the Discussion!

Posted-In: JefferiesAnalyst Color Long Ideas M&A Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

StockFirmActionPT
GOTUCitigroupDowngrades12.0
ATERRoth CapitalMaintains25.0
FMTXSVB LeerinkMaintains54.0
TALCitigroupDowngrades
PLXSLoop CapitalMaintains105.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com